Fujifilm
bd_51157bf200945e37 · schema v1 · pii pii-v1
Full breach record for Fujifilm →4 incidents on fileThreat-actor claim — not a regulatory filing
This row is a claim by the ransomware group Sarcoma on its public extortion blog. It has not been validated by the victim or any regulator. Treat attribution and counts as the threat actor's assertion until a regulatory filing or victim disclosure corroborates them.
Source: Ransomware.live
Post text · scraped from the leak site
Fujifilm has actively promoted the research and development of liposome formulations by harnessing its advanced nano-dispersion technology, analysis technology, and process technology cultivated and evolved through its wide range of product development. In 2017, the company began a U.S. Phase I clinical trial of FF-10832, a liposome-based agent that encapsulates the approved anti-cancer agent gemcitabine *** . In the preclinical mice studies on FF-10850 and FF-10832 *4 Fujifilm has observed the extension of the survival period as a result of immune checkpoint inhibitor *5 combination therapy. In addition, Fujifilm has been promoting the application of liposome for use with next-generation drugs such as nucleic acid drugs and gene therapy drugs. Looking towards future growth, in order to ensure a stable supply of high-quality liposome formulations, Fujifilm is developing a manufacturing facility for producing investigational and commercial drugs through its subsidiary, FUJIFILM Toyama.Geo: Singapore - Leak size: NO DATA 1 pdf - Contains: NO DATA 1 pdf
J jump to incidentP pin to compareR raw source
Incident timeline — mostly unverified
? — ?
Breach window unknown
Apr 5, 2025
Claim posted
—
No filing yet · watching
Compliance clocks stay unassessable until a regulatory filing lands. Dashed segments fill in automatically when corroboration arrives.
Claim → filing
—
Compliance clock
Not assessable
Evidence ladder
Attacker assertion only. Establishes: claim date, group, alleged victim.
Unlocks: incident narrative, operational impact. Still no compliance clock.
Unlocks: discovery date, data types, affected count, compliance clock.
Unlocks: materiality, stated response, full audit trail. Ceiling removed.
No regulatory filing corroborates this yet — it is the attacker's own assertion. Watch this entity to be notified the moment a filing corroborates or contradicts it.
Source ceiling
- actor name
- victim claim
- ransom/leak status
- discovery date
- materiality
- notification
- affected count
- confirmed data types
- compliance clock
The ✕ fields stay blank until a regulatory filing or victim disclosure lands.
sarcoma
According to ransomware.live, Sarcoma is a ransomware group that debuted in October 2024, immediately ranking among the top three most active groups globally and surpassing 116 documented victims by mid-2025, targeting mid-market companies across manufacturing, retail, healthcare, legal, and business services with roughly 50% of victims in the United States.